Anavex Life Sciences (AVXL)
NASDAQ:AVXL
Top Page
Anavex Life Sciences
(NASDAQ:AVXL)
Select Model
Select Model
Rating:46Neutral
Price Target:
$2.50
▼(-16.39% Downside)
Action:ReiteratedDate:03/26/26
The score is weighed down primarily by weak financial performance (no revenue, ongoing losses and cash burn) and bearish technical positioning (price far below key moving averages). The earnings call provides partial support via a strong cash runway and reduced expenses, but regulatory uncertainty—especially in the EU—keeps overall risk elevated, while valuation offers limited support given negative earnings and no dividend.
Positive Factors
Strong cash runway & no debt
A multi-year cash runway ($131.7M at Dec‑31, low quarterly cash burn) plus zero debt materially lowers near-term financing pressure. That durable liquidity profile gives management time to execute pivotal filings, sponsor confirmatory studies or seek partnerships without immediate dilution or refinancing risk.
Negative Factors
No revenue; persistent losses
As a development‑stage biotech with no product revenue and recurring multi‑million dollar losses, Anavex remains reliant on external financing or partnerships. Persistent negative cash flow erodes equity and constrains strategic flexibility over months to years absent successful monetization or sustained financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash runway & no debt
A multi-year cash runway ($131.7M at Dec‑31, low quarterly cash burn) plus zero debt materially lowers near-term financing pressure. That durable liquidity profile gives management time to execute pivotal filings, sponsor confirmatory studies or seek partnerships without immediate dilution or refinancing risk.
Read all positive factors
Anavex Life Sciences (AVXL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$277.09M
Dividend YieldN/A
Average Volume (3M)1.77M
Price to Earnings (P/E)―
Beta (1Y)1.68
Revenue GrowthN/A
EPS Growth-5.71%
CountryUS
Employees42
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding92,671,760
10 Day Avg. Volume3,223,684
30 Day Avg. Volume1,772,022
Financial Highlights & Ratios
PEG Ratio-4.26
Price to Book (P/B)8.00
Price to Sales (P/S)0.00
P/FCF Ratio-19.44
Enterprise Value/Market Cap0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.56
Forecast
1Y Price Target
$20.00Price Target Upside568.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.33
Revenue Forecast (FY)N/A
Anavex Life Sciences Business Overview & Revenue Model
Company Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinica...
How the Company Makes Money
Anavex Life Sciences primarily makes money through external financing rather than commercial product sales, because it is a clinical-stage company and, as of the latest public information available to me, it has no marketed products generating rec...
Anavex Life Sciences Earnings Call Summary
Earnings Call Date:Feb 09, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Positive
The call presents a cautiously optimistic tone: the company reports a strong cash position with multi-year runway, notable reductions in burn, positive clinical signals (especially in the AB-clear precision-medicine subgroup) and constructive regulatory engagement with the FDA. However, the CHMP negative opinion, a missed ADCS-ADL endpoint in the original EU submission, and remaining execution and regulatory obligations (including potential confirmatory post-approval studies) are meaningful near-term risks. Overall, positive operational and scientific developments outweigh the regulatory setbacks, but outcomes remain contingent on ongoing reexamination and further regulatory interactions.Positive Updates
Strong cash position and runway
Cash of $131.7 million at Dec 31 with no debt; cash used in operating activities of $7.1 million during the quarter; company anticipates cash runway of more than three years at current burn rate.
Negative Updates
CHMP negative opinion and regulatory uncertainty in EU
In December the CHMP adopted a negative opinion on the marketing authorization application for blarcamesine; company has requested EMA reexamination and expects the reexamination process to occur during the first half of the year (company described a 60+60-day response/review sequence plus rapporteur review). Approval is not guaranteed.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong cash position and runway
Cash of $131.7 million at Dec 31 with no debt; cash used in operating activities of $7.1 million during the quarter; company anticipates cash runway of more than three years at current burn rate.
Read all positive updates
Company Guidance
On the fiscal 2026 Q1 call (Feb 9, 2026) management gave specific operational and regulatory guidance: cash was $131.7M at Dec 31 with no debt and $7.1M of cash used in the quarter, implying a stated cash runway of more than three years at the current burn; Q1 R&D was $4.7M (down from $10.4M YoY) and G&A was $2.1M (down from $3.1M YoY), with a net loss of $5.7M or $0.06 per share; regulatory timelines include an EMA re‑examination process described as a 60+60‑day response window plus an additional ~60‑day rapporteur review (targeted in H1 2026) and a January Type C meeting with the FDA after which the company will submit the full Phase 2b/3 (Anavex 2‑73 AD‑004) data package toward next steps/NDA planning; programmatic updates include participation in the multiyear, EC‑funded Access AD initiative and a planned AD‑006 placebo‑controlled study in early AD, ongoing compassionate use in Rett and AD (Canada, UK, Australia), presentations/publications (CTAD, March 12 Johns Hopkins), pursuit of a CMA with a confirmatory post‑approval study if granted, and biomarker/genetic findings (COL24A1 prevalence estimated >70% in early AD) plus advancement of Anavex 3‑71 toward pivotal schizophrenia studies.Anavex Life Sciences Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
55
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -39.99M | -46.38M | -43.00M | -46.54M | -47.62M | -37.64M |
| Net Income | -39.95M | -46.38M | -43.00M | -47.51M | -47.98M | -37.91M |
Balance Sheet | ||||||
| Total Assets | 132.99M | 103.81M | 135.57M | 154.39M | 152.70M | 161.62M |
| Cash, Cash Equivalents and Short-Term Investments | 131.75M | 102.58M | 132.19M | 151.02M | 149.16M | 152.11M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 6.37M | 8.95M | 15.30M | 12.53M | 10.21M | 10.80M |
| Stockholders Equity | 126.62M | 94.87M | 120.26M | 141.85M | 142.49M | 150.82M |
Cash Flow | ||||||
| Free Cash Flow | -34.08M | -39.04M | -30.81M | -27.79M | -24.24M | -30.38M |
| Operating Cash Flow | -34.08M | -39.04M | -30.81M | -27.79M | -24.24M | -30.38M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 45.05M | 9.43M | 11.97M | 29.65M | 21.29M | 153.24M |
Anavex Life Sciences Technical Analysis
Negative
2.99
Price Trends
4.24
Negative
4.26
Negative
6.98
Negative
Market Momentum
-0.41
Positive
32.93
Neutral
22.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVXL, the sentiment is Negative. The current price of 2.99 is below the 20-day moving average (MA) of 3.94, below the 50-day MA of 4.24, and below the 200-day MA of 6.98, indicating a bearish trend. The MACD of -0.41 indicates Positive momentum. The RSI at 32.93 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AVXL.
Anavex Life Sciences Risk Analysis
Anavex Life Sciences disclosed 50 risk factors in its most recent earnings report. Anavex Life Sciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Anavex Life Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $385.42M | -2.29 | -65.76% | ― | ― | 18.39% | |
47 Neutral | $375.26M | -1.84 | -99.00% | ― | 407.86% | 30.35% | |
46 Neutral | $277.09M | -13.95 | -38.76% | ― | ― | -5.71% | |
45 Neutral | $258.47M | ― | -69.63% | ― | 158.54% | 66.90% | |
44 Neutral | $175.76M | -8.62 | 25.65% | ― | ― | 18.82% | |
44 Neutral | $119.57M | -3.07 | -75.73% | ― | ― | 4.71% |
* Healthcare Sector Average
AVXL
Anavex Life Sciences
2.99
-5.34
-64.11%
GALT
Galectin Therapeutics
2.67
1.35
102.27%
RCKT
Rocket Pharmaceuticals
3.55
-1.64
-31.60%
CLLS
Cellectis SA
3.41
2.25
193.97%
AUTL
Autolus Therapeutics
1.41
0.10
7.63%
PEPG
PepGen Inc.
1.73
0.63
57.27%
Anavex Life Sciences Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Anavex Withdraws EU Application for Blarcamesine in Alzheimer’s
Negative
Mar 25, 2026
On March 25, 2026, Anavex Life Sciences withdrew its application for EU marketing authorization of its lead candidate blarcamesine as an add-on therapy for early Alzheimer’s disease in adults, after feedback from the EMA’s Committee fo...
Business Operations and StrategyExecutive/Board Changes
Anavex Adds Veteran Healthcare Leader to Board of Directors
Positive
Feb 25, 2026
On February 20, 2026, Anavex Life Sciences’ board appointed healthcare executive Dr. Axel Paeger as an independent director, effective February 23, 2026, filling a board vacancy and aligning his compensation with other non-employee directors...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.